Oncology Business Management | Specialty

Treatments for Post-Docetaxel Prostate Cancer, Part II

December 12th 2012

Treatments for Post-Docetaxel Prostate Cancer, Part I

December 12th 2012

NCCN Guidelines for Advanced Prostate Cancer

December 12th 2012

Immunotherapy in Advanced Prostate Cancer, Part II

December 12th 2012

Immunotherapy in Advanced Prostate Cancer, Part I

December 12th 2012

Managing ADT-Associated Skeletal-Related Events

December 12th 2012

Prostate Cancer Management: Introduction and Overview

December 12th 2012

Rationalizing Treatment and Coverage Decisions With Predictive Biomarkers

December 11th 2012

Predictive biomarkers are beginning to help physicians assign value to associated therapies in terms of likelihood of benefit and benefit-to-risk profiles for individual patients.

FDA Approves Earlier Use of Abiraterone Acetate

December 10th 2012

The FDA has approved abiraterone acetate in combination with prednisone prior to chemotherapy for the treatment of men with metastatic castration-resistant prostate cancer.

Legal Considerations With Accountable Care Organizations

November 30th 2012

Oncologists should be aware that the need to refer patients between ACO members can raise legal issues for practices and should consider two key laws before participating.

FDA Approves Cabozantinib for Medullary Thyroid Cancer

November 29th 2012

The FDA approved cabozantinib, a multi-targeted tyrosine kinase inhibitor, for the treatment of metastatic medullary thyroid cancer.

Can Practices Successfully Dispense Oral Anticancer Agents In-House?

November 16th 2012

In-house dispensing of oral agents in the community oncology setting may provide a safer and more reliable and convenient way for patients to receive their medications.

Treatment and Cost Implications of Pertuzumab

November 15th 2012

Pertuzumab, a new HER2-positive breast cancer drug, is being launched at a 31% premium to the price of trastuzumab.

Developing Patient-Centered Medical Homes

November 14th 2012

Medical homes are physician-led healthcare teams that coordinate care for patients and typically rely on electronic methods for record-keeping, care coordination, and data collection.

FDA Grants Orphan Drug Status to Amatuximab for Malignant Pleural Mesothelioma

November 12th 2012

Amatuximab has received orphan drug status from the FDA to treat patients with malignant pleural mesothelioma, the most common form of mesothelioma.

Dr. Oh on Sequencing New Treatments for Prostate Cancer

November 12th 2012

William K. Oh, MD, from the Tisch Cancer Institute, discusses strategies for sequencing the new therapies that have been approved for treating castration-resistant prostate cancer.

How Can We Get Better Value in End-of-Life Care?

November 9th 2012

The last year of life is associated with high health expenditures in the United States, and the costs are increasingly focused on patients' last few months.

How Payers and Oncologists Really Feel About Clinical Pathways

November 6th 2012

Stakeholders weigh in on evidence-based pathway approach designed to decrease practice variation, improve outcomes, and reduce cost.

Which Practice Model Is Best for You?

October 31st 2012

Community oncologists must weigh multiple factors when deciding to consolidate or remain independent.

Management of Comorbidities in Early Breast Cancer

October 25th 2012